179 related articles for article (PubMed ID: 19887056)
41. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
Basak GW; Jaksic O; Koristek Z; Mikala G; Basic-Kinda S; Mayer J; Masszi T; Giebel S; Labar B; Wiktor-Jedrzejczak W;
Eur J Haematol; 2011 Jun; 86(6):488-95. PubMed ID: 21410533
[TBL] [Abstract][Full Text] [Related]
42. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T
Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373
[TBL] [Abstract][Full Text] [Related]
43. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
44. Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection.
Lanza F; Marchetti M; Zannetti BA
Transfus Apher Sci; 2023 Dec; 62(6):103830. PubMed ID: 37867056
[TBL] [Abstract][Full Text] [Related]
45. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
[TBL] [Abstract][Full Text] [Related]
46. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of mobilization efficacy with an extended interval following plerixafor administration.
Stump SE; Trepte M; Shaw JR; Grgic T; Ptachcinski JR; Sharf A; Riches M; Shea TC; Park YA; Alexander MD
J Oncol Pharm Pract; 2020 Oct; 26(7):1590-1597. PubMed ID: 32063103
[TBL] [Abstract][Full Text] [Related]
48. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Giralt S; Costa L; Schriber J; Dipersio J; Maziarz R; McCarty J; Shaughnessy P; Snyder E; Bensinger W; Copelan E; Hosing C; Negrin R; Petersen FB; Rondelli D; Soiffer R; Leather H; Pazzalia A; Devine S
Biol Blood Marrow Transplant; 2014 Mar; 20(3):295-308. PubMed ID: 24141007
[TBL] [Abstract][Full Text] [Related]
49. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
[TBL] [Abstract][Full Text] [Related]
50. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients.
Jantunen E; Penttilä K; Pyörälä M; Mahlamäki E; Kuittinen T; Nousiainen T
Bone Marrow Transplant; 2011 Feb; 46(2):308-9. PubMed ID: 20400986
[No Abstract] [Full Text] [Related]
51. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
[TBL] [Abstract][Full Text] [Related]
52. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
53. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
Milone G; Martino M; Leotta S; Spadaro A; Zammit V; Cupri A; Avola G; Camuglia MG; Di Marco A; Scalzulli P; Morelli M; Olivieri A; Tripepi G
Leuk Lymphoma; 2018 Jan; 59(1):42-48. PubMed ID: 28573902
[TBL] [Abstract][Full Text] [Related]
55. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Gregory KM; Rao KV; Armistead PM
Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
[TBL] [Abstract][Full Text] [Related]
56. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
58. Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.
Patel B; Pearson H; Zacharoulis S
Pediatr Blood Cancer; 2015 Aug; 62(8):1477-80. PubMed ID: 25755177
[TBL] [Abstract][Full Text] [Related]
59. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
60. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]